Neurogene Inc. 8-K

What Happened
Neurogene Inc. (NGNE) filed an 8-K on June 4, 2026 reporting the results of its 2026 Annual Meeting of Stockholders. The meeting, with 11,387,407 shares present (about 72.92% of voting power), elected two Class III directors—Robert Baffi and Rohan Palekar—to serve until the 2029 annual meeting. Stockholders also approved, on an advisory (non-binding) basis, the compensation of the company's named executive officers and ratified Deloitte & Touche LLP as the independent registered public accounting firm for 2026. Shareholders voted to hold future advisory votes on executive compensation every year; the company intends to hold annual advisory votes going forward.

Key Details

• Quorum/attendance: 11,387,407 shares present, ~72.92% of voting power (record date April 7, 2026).
• Director elections: Robert Baffi — 9,540,734 For / 548,736 Withheld (1,297,937 broker non-votes); Rohan Palekar — 10,058,331 For / 31,139 Withheld (1,293,937 broker non-votes).
• Advisory executive-pay vote: 9,991,445 For / 36,394 Against / 61,631 Abstain (1,297,937 broker non-votes).
• Auditor ratification: Deloitte & Touche LLP ratified — 9,345,925 For / 1,939,039 Against / 102,443 Abstain.
• Frequency vote: Stockholders chose annual advisory votes — One Year: 10,006,265; Two Years: 3,407; Three Years: 16,721 (63,077 abstentions; 1,297,937 broker non-votes).

Why It Matters
These outcomes confirm the board’s leadership slate and maintain the company’s existing compensation approach with strong, non-binding shareholder support. Ratification of Deloitte as auditor secures the company’s accounting oversight for 2026. The clear preference for annual advisory votes on executive pay signals ongoing shareholder interest in regular, transparent engagement on executive compensation—an item investors often watch for corporate governance and accountability.